Novosteo
Indiana · Founded 2017
About Novosteo
Novosteo, Inc. is a startup developing and delivering new drugs for the treatment of bone injury and diseases that impact patients' morbidity, mortality and loss of mobility and productivity associated with bone fractures, bone metastasis and infection. Scientific co-founders Stewart Low and Philip Low of Purdue University have created a proprietary chemistry approach to bone targeting and have discovered novel biologics that accelerate bone regeneration by delivering anabolic agents preferentially to fracture surfaces.
Company Facts
- Founded: 2017
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $8.0M
- Funding stage: M&A
- Last round: Series A (Jan 2021)
- Website: https://www.novosteo.com/
- Phone: 765-761-3912
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/novosteo-135407 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.